St. Olavs Hospital, Universitetssykehuset i Trondheim

Trondheim N-7030

3 studies enrolling now · 9 studies all time

What they study most

Alzheimer Disease, Cardiovascular Diseases, Cluster Headache, Episodic, Diabetes Mellitus, Type 2, Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extrapulmonary Neuroendocrine Cancer (epNEC), Heart Failure, Hypertension, Mesothelioma, Obesity, Small Cell Lung Cancer (SCLC)

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy — Recruiting now
• DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy — Recruiting now
• A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) — Completed
• Eptinezumab in Participants With Episodic Cluster Headache — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms. — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms — Completed
• BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease. — Completed
• Nintedanib (BIBF 1120) in Mesothelioma — Stopped early